What in silico modelling can offer opponents before the EPO
Marion Autissier, Denis Bourgarel
The first two articles in this series took the applicant’s perspective: how the EPO assesses in (...)
Practical advice on patent strategy in the pharmaceutical and biotech sectors
Marion Autissier, Denis Bourgarel
Our first article showed that in silico modelling is now becoming a feature of biomedical patent (...)
Fabrice Bircker, Stéphane Millet
As we recently announced in our article, 1,616 New Internet Extensions Coming Soon: Are You (...)
Fabrice Bircker, Stéphane Millet
An analysis of the 1,616 applications for new Internet extensions will be essential as soon as they (...)
Pharma and biotech: the patentability of in silico inventions before the EPO
Marion Autissier, Denis Bourgarel
When modeling replaces the laboratory in the biomedical field
An “in silico” invention is an (...)
Sandrine Bouvier-Ravon, François Jonquères
A year ago, Sandrine Bouvier-Ravon and François Jonquères, partners at Plasseraud IP Avocats, co- (...)
Bruno Loubet
T0799/24 “JFESteel”: an explicit manufacturing step is not mandatory to provide a technical effect (...)
Bruno Loubet
One of the key requirements that a European application must fulfill is the criterion of (...)
Bruno Loubet
At the European Patent Office (EPO), computer-implemented inventions, especially those involving (...)
Lilia Leghmizi
On 27 June 2023, in case T 438/19, Technical Board 3.3.03 referred key questions to the Enlarged (...)
Bruno Loubet
The decision T 1580/23 of the Boards of Appeal 3.5.05 of the European Patent Office (EPO) is an (...)
